Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 9/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778341 | 0.99 | PRCP (0.54) | PRCPHCRTR1HCRTR2USP30AADAT | |
| SCHEMBL17192927 | 0.95 | USP30 (0.53) | PRCPHCRTR1HCRTR2USP30 | |
| SCHEMBL12798598 | 0.95 | USP30 (0.53) | PRCPHCRTR1HCRTR2USP30 | |
| SCHEMBL9605087 | 0.92 | USP30 (0.59) | PRCPHCRTR1HCRTR2USP30 | |
| SCHEMBL7274515 | 0.90 | PRCP (0.53) | PRCPHCRTR1HCRTR2AADAT | |
| SCHEMBL12565381 | 0.89 | PRCP (0.46) | PRCPHCRTR1HCRTR2AADAT | |
| SCHEMBL2777207 | 0.88 | PRCP (0.51) | PRCPHCRTR1HCRTR2AADAT | |
| SCHEMBL16927373 | 0.88 | PRCP (0.51) | PRCPHCRTR1HCRTR2AADAT | |
| SCHEMBL16927371 | 0.88 | PRCP (0.51) | PRCPHCRTR1HCRTR2AADAT | |
| SCHEMBL10201512 | 0.87 | USP30 (0.54) | PRCPHCRTR1HCRTR2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623899-B2 | Bis-benzimidazole derivatives as hepatitis C virus inhibitors | Janssen Research & Development Ireland (IE) | 2014-01-07 | — | — | US | disclosed |
| US-8623899-B2 | Bis-benzimidazole derivatives as hepatitis C virus inhibitors | Janssen Research & Development Ireland (IE) | 2014-01-07 | — | — | US | disclosed |
| US-20120135953-A1 | Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2012-05-31 | — | — | US | disclosed |
| US-20120135953-A1 | Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135953-A1 | Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors | HAVCR2, ZC3HAV1, CCNI | PRCP 2043/4885HCRTR1 3448/4885HCRTR2 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.